ImClone deal

IMCL has proposed forming a new agreement with Chugai covering cancer and hematologic disorders, focused on products that interact with tyrosine kinase receptors. IMCL's antibody to the FLK-2 receptor could be part of a new agreement, IMCL said. The antibody has potential to separate stem cells and to treat acute and chronic myelogenous leukemias. ...